Proteomics in drug discovery.
Drug discovery is a prolonged process that uses a variety of tools from diverse fields. To accelerate the process, a number of biotechnologies, including genomics, proteomics and a number of cellular and organismic methodologies, have been developed. Proteomics development faces interdisciplinary challenges, including both the traditional (biology and chemistry) and the emerging (high-throughput automation and bioinformatics). Emergent technologies include two-dimensional gel electrophoresis, mass spectrometry, protein arrays, isotope-encoding, two-hybrid systems, information technology and activity-based assays. These technologies, as part of the arsenal of proteomics techniques, are advancing the utility of proteomics in the drug-discovery process.
ActivX Biosciences, Inc., 11025 North Torrey Pines Road, Suite 120, La Jolla, CA 92037, USA. jonb@activx.com
Jonathan
J
Burbaum
Gabriela M
GM
Tobal
D000818:Animals; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D008904:Miniaturization; D015336:Molecular Probe Techniques; D040901:Proteomics / Q000295:instrumentation / Q000379:methods; D013678:Technology, Pharmaceutical / Q000295:instrumentation / Q000379:methods